Fig. 4From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of ChinaForest plot of post-hoc subgroup analysis. HR, Hazard ratio; CI, Confidence interval; Meno, Menopausal status; Pre, Premenopausal status; CHT, Chemotherapy; MBC, Metastatic breast cancer; ET, Endocrine therapy; ER, Estrogen receptor; FULV, Fulvestrant; AI, Aromatase InhibitorsBack to article page